Immuron Limited (IMRN): Price and Financial Metrics
IMRN Stock Summary
- For IMRN, its debt to operating expenses ratio is greater than that reported by only 0.3% of US equities we're observing.
- With a year-over-year growth in debt of -100%, Immuron Ltd's debt growth rate surpasses merely 0% of about US stocks.
- Revenue growth over the past 12 months for Immuron Ltd comes in at 141.24%, a number that bests 96% of the US stocks we're tracking.
- Stocks that are quantitatively similar to IMRN, based on their financial statements, market capitalization, and price volatility, are POLA, LKCO, GENC, ELSE, and CBLI.
- IMRN's SEC filings can be seen here. And to visit Immuron Ltd's official web site, go to www.immuron.com.au.
IMRN Stock Price Chart Interactive Chart >
IMRN Price/Volume Stats
|Current price||$5.33||52-week high||$28.99|
|Prev. close||$5.32||52-week low||$1.81|
|Day high||$5.39||Avg. volume||66,889|
|50-day MA||$6.35||Dividend yield||N/A|
|200-day MA||$7.55||Market Cap||30.28M|
Immuron Limited (IMRN) Company Bio
Immuron Limited focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company was founded in 1994 and is based in Australia.
IMRN Latest News Stream
|Loading, please wait...|
IMRN Latest Social Stream
View Full IMRN Social Stream
Latest IMRN News From Around the Web
Below are the latest news stories about Immuron Ltd that investors may wish to consider to help them evaluate IMRN as an investment opportunity.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Key Points * Immuron’s Hyper-immune Bovine Colostrum, used to manufacture Travelan® and Protectyn®, demonstrated antiviral activity against the SARS-CoV-2/COVID-19 virus in laboratory studies. * A New Research Services Agreement has been executed with Monash University to advance the SARS-CoV-2 findings and to further research and identify the inhibitory substance/s in Immuron’s marketed products (IMM-124E). MELBOURNE, Australia, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, today is pleased to provide shareholders and the market with an update on progress made for the further development of th...
Immuron Shares Resume Trade Following Circuit Breaker To Upside; Stock Pulling Back From Session High, Still Up 30%
This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of …
Key Points * Immuron’s IMM-124E IND Program recommences * Uniformed Services University to recommence planned Travelers’ Diarrhea clinical study * COVID-19 \- Consultancy Agreement with Infectious Disease Epidemiologist at Wayne State University MELBOURNE, Australia, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today is pleased to provide shareholders and the market with an update on the planned clinical programs in Travelers’ Diarrhea (TD).The Board of Immuron has approved company plans to recommence the CMC related activities regarding its investigational drug IMM-124E required to supp...
MELBOURNE, Australia, July 23, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), (the “Company”), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today announced the closing of its previously announced registered direct offering of 1,066,668 American Depositary Shares (“ADSs”), each representing forty (40) of the Company’s ordinary shares, at a purchase price of $18.75 per ADS for gross proceeds of approximately US$20.0 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.The Company intends to use the net proceeds from this offering to fund Immuron’s research and development, preclinical and clinical programs, support ...
IMRN Price Returns